Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 17Myelodysplastic Syndromes 7Leukemia, Myelomonocytic, Chronic 4Ovarian Neoplasms 2Melanoma 2Leukemia 2Fallopian Tube Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor 1Sarcoma, Synovial 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, T-Cell 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia, Basophilic, Acute 1Breast Neoplasms 1Blast Crisis 1

Interventions

fludarabine phosphate 2fludarabine 2Tacrolimus 2Specimen Handling 2Mycophenolic Acid 2Cyclophosphamide 2Busulfan 2Biopsy 2venetoclax 1veliparib 1tagraxofusp 1decitabine and cedazuridine drug combination 1Whole-Body Irradiation 1Topotecan 1Thiotepa 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Melphalan 1Injections 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Decitabine 1Cytarabine 1Cyclosporine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Myelodysplastic-Myeloproliferative Diseases × Decitabine × Clear all
NCT05038592 2026-04-14

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
64 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡